In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Millennium Prospers Under Takeda--But Will Takeda Get Full Value?

Executive Summary

In losing its autonomy as an independently traded entity, Millennium has finally gained the freedom to become a larger player in the oncology space. One year after being acquired by Takeda, the biotech must no longer demonstrate to Wall Street regular quarterly earnings from Velcade, its only product, while trying to fund additional trials and build its pipeline. The success of this new business model fashioned by Takeda for its acquisition is still an open question, but it could provide a winning formula for Big Pharma companies in dire need of rejuvenated pipelines.
Advertisement

Related Content

With Nycomed, Takeda Satifies Both Strategic And Financial Objectives
Astellas Wins OSI But Victory Comes At A Price
Pfizer's Increasingly Specialist Focus
Pfizer's Increasingly Specialist Focus
Eli Lilly's Oncology Focus
Eli Lilly's Oncology Focus
Takeda's Global Ambition
Takeda's Global Ambition
Takeda/ Millennium: The Price is Right
Genzyme Breaks a Biotech Taboo: The Hostile Bid For AnorMED

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003328

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel